Literature DB >> 9436971

The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.

N Ratcliffe1, W Wells, K Wheeler, V Memoli.   

Abstract

The combination of in situ hybridization and immunohistochemical techniques can successfully identify viral DNA/RNA in specific subsets of cellular populations. We recently modified this method to evaluate amplification of the oncogene Her2/neu and overexpression of its protein c-erbB-2 in a series of 15 breast carcinomas. This combination allows the simultaneous evaluation of the oncogene and its corresponding protein expression in single cells and specific cellular populations in histologic tissue sections. Double staining demonstrated heterogeneity within breast carcinomas. In addition, both nuclear and cytoplasmic signals were often detected in morphologically normal-appearing adjacent breast epithelium. The ability to view both the oncogene and its corresponding protein in single cells offers a unique look at the biology of c-erbB-2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436971

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Novel bright field molecular morphology methods for detection of HER2 gene amplification.

Authors:  Raymond Tubbs; James Pettay; David Hicks; Marek Skacel; Richard Powell; Tom Grogan; James Hainfeld
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

2.  Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma.

Authors:  H Kaya; T Ragazzini; E Aribal; I Güney; E Kotiloglu
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

4.  Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.

Authors:  Emad A Rakha; Islam M Miligy; Cecily M Quinn; Elena Provenzano; Abeer M Shaaban; Caterina Marchiò; Michael S Toss; Grace Gallagy; Ciara Murray; Janice Walshe; Ayaka Katayama; Karim Eldib; Nahla Badr; Bruce Tanchel; Rebecca Millican-Slater; Colin Purdie; Dave Purnell; Sarah E Pinder; Ian O Ellis; Andrew H S Lee
Journal:  Br J Cancer       Date:  2021-03-24       Impact factor: 7.640

5.  Prognostic significance of HER2 gene amplification according to stage of breast cancer.

Authors:  Yong-Seok Kim; Yong Sung Won; Kyung Shin Park; Byung Joo Song; Jeong Soo Kim; Se Jeong Oh; Hae Myung Jeon; Sang Seol Jung; Woo-Chan Park
Journal:  J Korean Med Sci       Date:  2008-06       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.